Skip to main content
TipRanks
Go Ultimate75% OFF

Eric Devroe Insider Profile

11 Followers

Eric Devroe, COO at Acrivon Therapeutics, Inc., holds 146.35K shares in Acrivon Therapeutics, Inc. (Ticker: ACRV). Most recently, Eric Devroe Sold 604 shares of Acrivon Therapeutics, Inc. on Aug 20, 2026 for an estimated value of $1.21K.

Eric Devroe's Trading History

ACRV
Acrivon Therapeutics, Inc.
Aug 20, 2026COOInformative Sell1.21K$209.28K
ACRV
Insider Shares: 146.35K (0.34%)
DateTransactionAmountNo. of SharesPrice per ShareProfitLink to Report
Aug 20, 2026Informative Sell$1.21K604$2.01+34.00%
May 20, 2026Uninformative Buy$0.0072,981$0.00―
May 18, 2026Uninformative Sell$1.18K613$1.92―
Feb 18, 2026Uninformative Sell$1.18K723$1.63―
Jan 15, 2026Informative Buy$17.20K10,000$1.72+17.60%

You May Also Like

Eric Devroe insider profile FAQ

What is the percentage of profitable transactions made by Eric Devroe?
The percentage of profitable transactions made by Eric Devroe is 100%.
What is the average return per transaction made by Eric Devroe?
The average return per transaction made by Eric Devroe is 25.80%.
What stocks does Eric Devroe hold?
Eric Devroe holds: ACRV stocks.
What was Eric Devroe’s latest transaction?
Eric Devroe’s latest transaction was an Informative Sell of $1.21K.
What was Eric Devroe's most profitable transaction?
Eric Devroe’s most profitable transaction was an Informative Sell of ACRV stock on August 20, 2026. The return on the trade was 34.00%.
What is Eric Devroe's role in Acrivon Therapeutics, Inc.?
Eric Devroe's role in Acrivon Therapeutics, Inc. is COO.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.

TipRanks measures corporate insiders by the stock transactions they report to the SEC. See how TipRanks ranks experts and calculates performance.